Eating Disorder Clinical Trials 2023

Browse 39 Eating Disorder Medical Studies Across 27 Cities

4 Phase 3 Trial · 45 Eating Disorder Clinics

Reviewed by Michael Gill, B. Sc.
10 Eating Disorder Clinical Trials Near Me
Top Hospitals for Eating Disorder Clinical Trials
Image of Department of Psychiatry, Eating and Weight Disorders Program in New York.
Department of Psychiatry, Eating and Weight Disorders Program
New York
3Active Trials
0All Time Trials for Eating Disorder
2022First Eating Disorder Trial
Image of Yale Department of Psychiatry in Connecticut.
Yale Department of Psychiatry
New Haven
3Active Trials
0All Time Trials for Eating Disorder
2019First Eating Disorder Trial
Image of Drexel University, Stratton Hall in Pennsylvania.
Drexel University, Stratton Hall
Philadelphia
2Active Trials
0All Time Trials for Eating Disorder
2020First Eating Disorder Trial
Image of Lindner Center of HOPE in Ohio.
Lindner Center of HOPE
Mason
2Active Trials
0All Time Trials for Eating Disorder
2015First Eating Disorder Trial
Image of Mayo Clinic in Rochester in Minnesota.
Mayo Clinic in Rochester
Rochester
1Active Trials
1All Time Trials for Eating Disorder
2012First Eating Disorder Trial
Top Cities for Eating Disorder Clinical Trials
Image of Boston in Massachusetts.
Boston
4Active Trials
Neuroendocrine Unit Research CenterTop Active Site
Image of New York in New York.
New York
4Active Trials
Department of Psychiatry, Eating and Weight Disorders ProgramTop Active Site
Eating Disorder Clinical Trials by Phase of TrialEating Disorder Clinical Trials by Age Group
< 18 Eating Disorder Clinical Trials
2Active Eating Disorder Clinical Trials
Most Recent Eating Disorder Clinical TrialsTop Treatments for Eating Disorder Clinical Trials
Treatment Name
Active Eating Disorder Clinical Trials
All Time Trials for Eating Disorder
First Recorded Eating Disorder Trial
LDX
2
2
2019
FBT-PC delivered by a primary care provider
1
1
2023
TNX-1900
1
1
2023
Facing Eating Disorder Fears Condition
1
1
2022
Repetitive Transcranial Magnetic Stimulation
1
1
2022

What Are Eating Disorder Clinical Trials?

Eating disorders are severe conditions linked with eating behaviors that can significantly impact an individual's overall physical and mental health. The eating disorders include binge eating, bulimia, and anorexia.

In these eating disorders, patients are too focused on their body shape and weight, resulting in unhealthy eating habits and causing nutrition deficiency. Eating disorders can harm bones, the digestive system, and the heart.

Since these eating disorders typically impact young adults and teens, resulting in significant health issues, it is essential to conduct clinical trials to find a way to prevent and treat these conditions.

Why Is Eating Disorder Being Studied Through Clinical Trials?

Eating disorders impact about 9% of individuals globally and 28.8 million individuals in the US. At least once in their lifetime, around 0.4% of women and 0.1% of men suffer from anorexia nervosa.

Eating disorders are often linked with mental health issues and increase the chances of medical complications and suicide risk. Clinical trials are needed to find effective treatments and early detection to prevent and ensure full recovery from eating disorders.

What Are The Types of Treatments Available For Eating Disorders?

The eating disorder treatment varies based on the type of eating disorder and the specific needs of the individual. The treatments usually include a combination of the following:

  • Maudsley approach: This is a family therapy to help parents of teen kids dealing with anorexia.
  • Medications: This also helps treat other conditions with eating disorders, like depression or anxiety.
  • Nutrition counseling: This helps improve eating habits and teaches the patients to create nutritious meal plans.
  • Psychotherapy: The right therapy is established based on the condition of the patient. Cognitive behavioral therapy (CBT) is commonly used to help control emotions and behaviors.

What Are Some Recent Breakthrough Clinical Trials For Eating Disorders?

2023: Research has found that Psilocybin is not just a good depression treatment but can also help treat eating disorders like binge eating, bulimia, and anorexia. The results show the efficacy and safety of Psilocybin in treating eating disorders. However, there is a need to conduct more clinical trials and research on eating disorders and Psilocybin.

2019: FDA granted approval for dasotraline as a treatment for those with severe or moderate eating disorders. This drug is a novel norepinephrine and dopamine reuptake inhibitor, used once a day, and has shown positive results in treating binge eating disorder. The 12-week placebo-controlled, randomized clinical trial found that dasotraline was well-tolerated and showed positive results.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Eating Disorder Clinical Trials Research?

Eating Disorder Foundation: This is a non-profit company dedicated to assisting individuals battling with eating disorders by raising awareness, offering free support, and supporting research and clinical trials to eliminate and prevent eating disorders.

Dr. Stephanie Knatz Peck: Dr. Peck is a clinical psychologist and professor specializing in treating eating disorders. She plays an integral role in developing novel clinical treatments and has published a treatment manual to provide guidelines for loved ones to help an eating disorder patient. Dr. Peck is involved in evaluating, delivering, and developing psychedelic-assisted treatments for eating disorders and is currently co-investigating a study to evaluate psilocybin therapy for anorexia.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: August 14th, 2023

References1 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. https://pubmed.ncbi.nlm.nih.gov/115569412 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. https://pubmed.ncbi.nlm.nih.gov/115569413 Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. https://pubmed.ncbi.nlm.nih.gov/167171714 Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. https://pubmed.ncbi.nlm.nih.gov/167171715 Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146. https://pubmed.ncbi.nlm.nih.gov/176953436 Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. https://pubmed.ncbi.nlm.nih.gov/176953437 Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. doi: 10.1016/s1389-9457(00)00065-4. https://pubmed.ncbi.nlm.nih.gov/114382468 Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. https://pubmed.ncbi.nlm.nih.gov/114382469 Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985 Sep;10(3):141-6. https://pubmed.ncbi.nlm.nih.gov/405326110 Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704. https://pubmed.ncbi.nlm.nih.gov/22193671